(Q40437917)

20 September 2017

1 reference

title

The plasminogen activation system and its role in lung cancer. A review (English)

1 reference

20 September 2017

H. Pappot

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7600025

6 June 2024

N. Brünner

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7600025

6 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7600025

6 June 2024

publication date

1 March 1995

1 reference

full work available at URL

20 September 2017

https://api.elsevier.com/content/article/PII:016950029400408F?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

https://api.elsevier.com/content/article/PII:016950029400408F?httpAccept=text/plain

6 June 2024

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

6 June 2024

1 reference

20 September 2017

12

1 reference

20 September 2017

1-2

1 reference

20 September 2017

1-12

1 reference

Plasminogen activator inhibitors: hormonally regulated serpins

20 September 2017

2

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors

6 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Differences in the repertoires of basement membrane degrading enzymes in two carcinoma sublines with distinct patterns of site-selective metastasis.

6 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex

6 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

CULTIVATION IN VITRO OF MALIGNANT TUMORS.

6 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Prevention of metastasis by inhibition of the urokinase receptor

6 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Tumor necrosis factor stimulates urokinase-type plasminogen activator and inhibitor type 1 production in A549 lung carcinoma cells: treatment of monolayer and tridimensional cultures

6 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer

6 June 2024

13

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Isolation of cDNA sequences coding for a part of human tissue plasminogen activator

6 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Plasminogen Activation by Receptor-Bound Urokinase

6 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

The urokinase receptor: involvement in cell surface proteolysis and cancer invasion

6 June 2024

17

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Mechanism of the Proteolytic Activity of Malignant Tissue Cells

6 June 2024

19

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients

6 June 2024

20

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Immunohistochemical Study of Tumor Cell-associated Plasminogen Activators and Plasminogen Activator Inhibitors in Lung Carcinomas

6 June 2024

23

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans

6 June 2024

24

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis

6 June 2024

25

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain

6 June 2024

26

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer

6 June 2024

27

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Urokinase-type plasminogen activator and its specific receptor in high metastatic and non-metastatic cell lines derived from human lung adenocarcinoma

6 June 2024

28

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors

6 June 2024

29

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Regulation of the plasminogen activator system in non-small cell lung cancer cell lines by growth factors EGF, TGF-α and TGF-β

6 June 2024

30

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Immunohistochemical evidences of prognostic parameters associated with tumor development of pulmonary adenocarcinoma

6 June 2024

31

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer

6 June 2024

32

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma

6 June 2024

33

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta

6 June 2024

34

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

CHARACTERISTICS OF GROWTH OF SARCOMA AND CARCINOMA CULTIVATED IN VITRO.

6 June 2024

35

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Okadaic acid strongly increases gene transcription, mRNA and protein level for the urokinase receptor in human A549 cells

6 June 2024

36

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells

6 June 2024

37

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin

6 June 2024

38

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer

6 June 2024

39

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Physiological mechanisms for metalloproteinase activation

6 June 2024

40

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination

6 June 2024

41

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Immunohistochemical localization of coagulation, fibrinolytic and antifibrinolytic markers in adenocarcinoma of the lung

6 June 2024

42

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer

6 June 2024

43

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues

6 June 2024

44

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma

6 June 2024

45

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Antibodies to plasminogen activator inhibit human tumor metastasis

6 June 2024

46

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse

6 June 2024

47

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion

6 June 2024

48

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli

6 June 2024

51

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas

6 June 2024

54

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma

6 June 2024

55

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer

6 June 2024

57

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor

6 June 2024

60

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Cell-associated plasminogen activation: regulation and physiological functions

6 June 2024

61

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Differential protease expression by cutaneous squamous and basal cell carcinomas

6 June 2024

62

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas

6 June 2024

63

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture

6 June 2024

64

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Three types of human lung tumour cell lines can be distinguished according to surface expression of endogenous urokinase and their capacity to bind exogenous urokinase

6 June 2024

66

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma

6 June 2024

67

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

The plasminogen activator/plasmin system

6 June 2024

69

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Urokinase receptors in lung cancer and normal lung

6 June 2024

70

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Purification and characterization of a melanoma cell plasminogen activator

6 June 2024

72

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung

6 June 2024

73

1 reference

https://api.crossref.org/works/10.1016/0169-5002(94)00408-F

6 June 2024

Identifiers

1 reference

20 September 2017

1 reference